Overview

  • Product nameCGP 55845 hydrochloride
  • Description
    Potent, selective GABAB antagonist
  • Alternative names
    • CGP55845 hydrochloride
  • Biological description

    Potent, selective GABAB antagonist (IC50 = 5 nM). Prevents agonist binding (pKi = 8.35) and blocks GABAB responses to Baclofen (ab120325). Inhibits GABA and glutamate release (pEC50 values are 8.08 and 7.85, respectively). Stimulates glucose induced insulin secretion.

  • Purity> 99%

Properties

    References for CGP 55845 hydrochloride (ab120337)

    This product has been referenced in:
    • Salah A & Perkins KL Effects of subtype-selective group I mGluR antagonists on synchronous activity induced by 4-aminopyridine/CGP 55845 in adult guinea pig hippocampal slices. Neuropharmacology 55:47-54 (2008). Read more (PubMed: 18538357) »
    • Braun M  et al. GABAB receptor activation inhibits exocytosis in rat pancreatic beta-cells by G-protein-dependent activation of calcineurin. J Physiol 559:397-409 (2004). Read more (PubMed: 15235087) »
    • Vinay L & Clarac F CGP 35348 and CGP 55845A block the baclofen-induced depression of dorsal root evoked potentials in lumbar motoneurons of the neonatal rat. Neurosci Lett 214:103-6 (1996). Read more (PubMed: 8878094) »
    • Waldmeier PC  et al. GABA and glutamate release affected by GABAB receptor antagonists with similar potency: no evidence for pharmacologically different presynaptic receptors. Br J Pharmacol 113:1515-21 (1994). Read more (PubMed: 7889310) »

    See all 10 Publications for this product

    Product Wall

    Thank you for contacting us.


    As discussed over the phone the solubility of CGP 55845 hydrochloride is 100 mM in DMSO. The information on the CoA was unfortunately an error. Thank you for bringing this to our attention. This will be alte...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"